abstract | Pancreatic cancer has a poor prognosis and is often diagnosed at an advanced stage, which makes it difficult to treat. The low survival rate of patients with pancreatic cancer points towards an increased need for novel therapeutic and chemopreventive strategies and also early detection of this disease. Increased consumption of fruits and vegetables has been associated with a reduced risk of pancreatic cancer. Synthetic and natural, diet-derived bioactive compounds have been evaluated as pancreatic cancer chemopreventive agents and have demonstrated various degrees of efficacy in cellular and in vivo animal models. Some chemopreventive agents (for example, curcumin or resveratrol) have also been reported to sensitize pancreatic cancer cells to standard chemotherapeutic drugs (for example, gemcitabine or erlotinib), which suggests that chemopreventive agents could potentially be used as potentiators of standard chemotherapy. Few clinical trials of pancreatic cancer chemopreventive agents have been completed and some are in early phases. Further development of pancreatic cancer chemopreventive agents may prove to be tremendously valuable for individuals at high risk of developing pancreatic cancer and patients who present with premalignant lesions. This Review discusses the current state of the pancreatic cancer chemoprevention field and highlights the challenges ahead.
Introduction
Despite important progress in the treatment of pancreatic cancer, the survival rate of patients with this disease has not significantly improved over the past few decades. Pancreatic cancer is the fourth leading cause of cancerrelated deaths in the usa, with a 5-year survival rate of less than 5%. 1 in 2009 it was estimated that in the usa alone 42,470 men and women would be diagnosed with pancreatic cancer, and 35,240 people would die from this disease. 1 owing to their genetic predisposition, members of pancreatic-cancer-prone families, including those with a history of Peutz-Jeghers syndrome, hereditary pancreatitis or familial atypical multiple mole melanoma (Fammm), are at the highest risk of developing pancreatic cancer. 2, 3 other factors associated with an increased risk of developing pancreatic cancer include advancing age, tobacco smoking, chronic pancreatitis, type ii diabetes, obesity, and a high dietary intake of fried foods and red meat. [2] [3] [4] [5] [6] [7] several epidemiological studies have reported that increased consumption of fresh fruits and vegetables is associated with a reduced risk of pancreatic cancer, 2 although other studies have reported null results. 8 Pancreatic cancer is often diagnosed at an advanced stage and it is highly resistant to conventional chemotherapy and radiation therapy, which makes it difficult to treat. Gemcitabine and erlotinib represent the current FDa-approved standard chemotherapy for pancreatic cancer, but produce only a modest survival benefit in patients with advanced disease.
9-13 the low survival rate of patients with pancreatic cancer points towards an increased need for novel therapeutic and chemoprevention strategies and also early detection of this disease. this review discusses the current state of the field of pancreatic cancer chemoprevention and highlights the current strategies and challenges for chemoprevention of pancreatic cancer.
Pathogenesis of pancreatic cancer
Pancreatic cancer is generally thought to arise from pancreatic ductal epithelial cells, although acinar cells may also be a source of pancreatic neoplasia. 14, 15 in addition, other differentiated or progenitor/stem cells have also been suggested as the potential origin for the develop ment of pancreatic cancer. 16 For instance, insulinexpressing endocrine cells of the adult pancreas have been shown to transdifferentiate and give rise to exocrine neoplasia under conditions of chronic pancreatic injury. 16 the progression from normal epithelium to pancreatic cancer is associated with the accumulation of several genetic mutations, and seems to gradually evolve via precursor lesions, called pancreatic intraepithelial neoplasias (Panins) . activation of the oncogene KRAS and inactivation of tumor suppressor genes-for example CDKN2A (also known as p16), SMAD4 (also known as DPC4), and TP53 (also known as p53)-are common events in the development of pancreatic cancer.
14 KRAS mutations occur early in the development of pancreatic cancer and are the most frequent mutations associated with pancreatic adenocarcinoma (found in 75-90% of patients with pancreatic cancer). 5, 17, 18 activating mutations in the KRAS gene occur both in pancreatic ductal adenocarcinoma and in Panins, and increase in frequency with disease progression. 14, 15 epidermal growth factor (eGF), hepatocyte growth factor (HGF), and insulin-like growth factor 1 (iGF1) and their corresponding receptors are also frequently overexpressed in pancreatic cancer. [19] [20] [21] the main signaling pathways and the molecular pathogenesis of pancreatic cancer were reviewed by wong and lemoine in 2009. 9 the survival pathway phosphatidylinositol-3-kinase (Pi3K)-aKt is frequently activated in many cancers, including pancreatic cancer. the Pi3K-aKt pathway is activated in approximately 60% of pancre atic cancers 9 and represents a prog nostic indicator for pancreatic ductal adenocarcinoma. 22 Constitutive activation of the signal transducer and activator of trans cription 3 (stat3) pathway is frequently detected in pancre atic cancer and may contribute to increased growth, angiogenesis and metastasis of pancreatic cancer. 23, 24 nuclear factor kappa B (nFκB) controls different biological processes, such as inflammation, apoptosis and the cell cycle, and is a key antiapoptotic trans cription factor in pancreatic ductal adeno carcinoma. 25 nFκB activa tion has been reported in pancreatic cancer cells, in animal models of pancreatic cancer and in human pancreatic tissue. 26, 27 Pancreatic cancer is associated with chronic inflammation. overexpression of inflammatory markers, such as cyclooxygenase 2 (CoX2), inducible nitric oxide synthase (inos), 5-lipoxygenase (5loX), and elevated levels of C-reactive protein are associated with poor survival of patients with pancreatic cancer. 4, 28 Disruption of notch and Hedgehog signaling pathways, which are important during embryonic development, has been reported in the pathogenesis of pancreatic cancer. 29 the notch signaling pathway is relatively inactive in normal adult pancreatic tissue, but shows moderate to high activity in metaplastic ductal epithelium, Panin2 and pancreatic ductal adenocarcinoma tissue. 15, 29 active notch signaling can synergize with KRAS activation to induce the formation of Panins. 15 activation of the Hedgehog signaling pathway has been implicated in the initiation of pancreatic ductal neoplasia and exhibits a graded increase in activation in late-stage lesions and pancreatic carcinomas. 30 
Key points
Pancreatic cancer has a low survival rate, which has not improved in the past ■ few decades; current chemotherapeutic treatment is not effective Figure 1 illustrates the effect of potential pancreatic cancer chemopreventive agents on multiple pathways involved in the pathogenesis of pancreatic cancer. agents developed primarily as cancer chemo preventive agents have also been proposed for chemotherapy, either as standalone drugs or as sensitizers to standard chemotherapeutic drugs (tables 1 and 2).
Curcumin
Curcumin (diferuloylmethane) is a bioactive component of tumeric, which is a spice derived from the rhizome of the plant Curcuma longa. Curcumin has been extensively studied over the past few decades and is known to have numerous biological activities. 31, 32 Cellular studies have demonstrated that curcumin inhibits the proliferation of pancreatic cancer cells and suppresses the activation of nFκB.
33,34 rela, the p65 subunit of nFκB, is constitutively activated in approximately 67% of human pancreatic adenocarcinomas, but not in normal pancreatic tissues. 33 wang et al. showed that curcumin inhibits the Dna-binding activity of rela and potentiates apoptotic cell death induced by paclitaxel in mDaPanc28 pancreatic cancer cells.
33 in other studies, curcumin was reported to suppress CoX2 and epidermal growth factor receptor (eGFr) expression and inhibit extracellular signal-regulated kinase (erK) 1 and 2 activity in P34 pancreatic cancer cells. 35, 36 Curcumin also downregulates the notch signaling pathway (through crosstalk between notch and nFκB signaling pathways) in association with inhibition of cell growth and induction of apoptosis in BxPC3 and PanC1 pancreatic cancer cells. 37 in a study by sun et al., curcumin was reported to alter specific microrna (mirna) expression in BxPC3 human pancreatic cancer cells, upregulating mirna22 and downregulating mirna199a*. 38 upregulation of mirna22 was associated with downregulation of two of its target genes and their proteins, the transcription factor sP1 and the estrogen receptor 1 protein (esr1), which is also expressed by pancreatic cancer cells. 38 in combinational chemotherapy studies, curcumin has been reported to sensitize pancreatic cancer cells to reViews gemcitabine, 34,36 celecoxib 39 and paclitaxel 33 (table 1) . in an orthotopic animal model in which human pancreatic cancer cells (miaPaCa2) were implanted in the pancreas of athymic nude mice, curcumin (1 g/kg, once daily by mouth) enhanced the antitumor activity of gemcitabine (25 mg/kg, twice weekly, intraperitoneal injection) by inhibiting cell proliferation, angiogenesis and nFκB-regulated gene products (cyclin D1, BCl2, BCl-xl, c-myc, CoX2, and survivin).
34 swamy et al. showed that the combination of 0.2% curcumin with 15% fish oil (high in n-3 fatty acids) acts synergistically to inhibit pancreatic cancer cell growth in a xenograft model (BxPC3) of pancreatic cancer in association with downregulation of proinflammatory proteins CoX2, 5loX, inos, and upregulation of cyclin-dependent kinase inhibitor p21. 40 Curcumin has a low bioavailability, but is well tolerated (up to 8 g/day) without showing dose-limiting toxicities.
41-43 oral administration of 4-8 g of curcumin results in peak plasma levels of 0.41-1.75 μmol/l. 31 although free plasma levels may not reflect tissue levels, in vitro studies suggest that microgram levels are required for activity in pancreatic cancer. 31 to increase the bioavailability of curcumin, three synthetic curcumin analogues-Flll11 and Flll12 44 and difluoro compound CDF 45 -have been synthesized and found to be more effective than natural curcumin at inhibiting cell viability and inducing apoptosis in pancreatic cancer cells in vitro. to enhance curcumin absorption, li et al. encapsulated curcumin in liposomes and administered these intravenously for systemic delivery. 46 the authors found that liposomeencapsulated curcumin (40 mg/kg, three times per week) inhibited the growth of BxPC3 and miaPaCa2 human pancreatic cancer cells in nude mice xenografts by inducing apoptosis and suppressing angiogenesis. 46 several clinical trials of curcumin in patients who have pancreatic cancer are currently in progress (table 2) . Curcumin is being used either alone or in combination with gemcitabine or nsaiDs. in a phase ii trial of curcumin (8 g daily), which is still ongoing, the results for the first 25 patients included in the study have been published and show that curcumin is well tolerated and has biological activity in some patients with advanced pancreatic cancer. 47 Circulating curcumin was detected in glucuronide and sulfate conjugate forms at low levels (steady-state level at day 3 was 22-41 ng/ml), which confirms its poor oral bioavailability. 47 Despite these suboptimal plasma levels, a biological effect was observed following administration of curcumin, with down regulated expression of nFκB, CoX2, and phosphorylated stat3 in peripheral blood mononuclear cells of patients with pancreatic cancer. CoX2 inhibitors Cyclooxygenases (CoXs) are enzymes that are responsible for the conversion of arachidonic acid to prostaglandins. CoX2 is an isoform that is induced in response to growth factors, cytokines and tumor promoters. 48 in normal pancreatic tissue CoX2 is detected only in islet cells, and not in acinar or ductal cells. 48 CoX2 is overexpressed in pancreatic cancer [49] [50] [51] and therefore represents a specific target for pancreatic cancer treatment and prevention.
several CoX2 inhibitors have been evaluated for the treatment and/or prevention of pancreatic cancer. Celecoxib is a selective CoX2 inhibitor that has been shown to prevent N-nitrosobis (2-oxopropyl) amine (BoP)-induced pancreatic cancer in syrian hamsters 52 and to significantly reduce tumor growth in pancreatic cancer xenografts in athymic nude mice. 53 Celecoxib was shown to suppress vascular endothelial growth factor (veGF) gene expression by suppressing sP1 transcriptional activity and to reduce angiogenesis and metastasis in pancreatic cancer in in vitro and in vivo studies. 39 in another study, mukherjee et al. showed that the combina tion of celecoxib with a novel mucin-1 (muC1)-based vaccine and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of Panins to invasive pancreatic ductal adeno carcinomas in a transgenic Kras G12D animal model that expresses human muC1 as a self-molecule. 55 a phase ii trial of gemcitabine in combination with celecoxib (400 mg twice a day) has been conducted, but the results are inconclusive and suggest that higher doses of celecoxib may be necessary to achieve significant antitumor activity. 56 a phase iii trial of gemcitabine, celecoxib and curcumin is currently in progress. 57 other CoX2-specific and nonspecific nsaiDsincluding aspirin, nimesulide, etodolac, sulindac, indomethacin, phenylbutazone and ns398-have been evaluated for the prevention and/or treatment of pancre atic cancer and have shown efficacy in cellular and animal models. 50 61 in another prospective study, which was conducted by schernhammer et al., an extended period of regular aspirin use was associated with an increased risk of pancreatic cancer in women in the us nurses' Health study. 62 women who reported more than 20 years of regular aspirin use had an increased risk of pancreatic cancer (rr 1.58, 95% Ci 1.03-2.43, P = 0.01). 62 green and black teas Green and black teas are derived from the plant Camellia sinensis (unfermented and fermented, respectively), and contain a series of polyphenols that act as powerful antioxidants. in a cellular study, epigallocatechin-3-gallate (eGCG), the major polyphenol extracted from green tea, was shown to suppress human pancreatic carcinoma cell growth and invasion. 63 lyn-Cook et al. demonstrated significant inhibition of cell growth in vitro in human pancreatic cancer cells treated with black and green tea extracts, a mixture of green tea polyphenols, and the purified polyphenols epicatechin-3-gallate and eGCG, in association with decreased expression of the KRAS gene. 64 in animal models, oral intake of a 0.1% solution of green tea catechins has a protective effect against the oxidative stress induced by BoP in the pancreas of syrian hamsters by reducing the tissue concentration of lipid peroxides and the amount of 8-hydroxydeoxyguanosine in nuclear Dna. 65 in another study, green tea polyphenols significantly reduced hyperplasia and the total number of duct lesions induced by BoP in syrian hamsters when used either alone or in combination with palm carotene. 66 several case-control and prospective studies have examined the association between tea consumption and pancreatic cancer risk, with varying results. increased tea consumption was associated with a decreased risk of pancreatic cancer in some studies, [67] [68] [69] [70] while others found no association between tea intake and pancreatic cancer risk. [71] [72] [73] [74] [75] [76] no clinical trials on the effect of tea extracts or purified tea polyphenols against pancre atic cancer have been reported so far, although the chemopreventive effects of green tea extracts are currently being investigated in clinical trials of lung, breast and prostate cancer. 57 Phase i pharmacokinetic studies of two green tea polyphenol formulations (eGCG and poly phenon e) revealed that, in general, they are well tolerated by healthy individuals, with mild adverse effects. 77, 78 Peak plasma eGCG levels of 0.4-0.8 μmol/l were achieved after the administration of these formulations at doses equivalent to the eGCG content of 8-16 cups of green tea. 77, 78 β-Carotene β-Carotene is a carotenoid that is found in many yellow and red fruits and vegetables, and in dark green, leafy vegetables. β-carotene inhibits the development of BoP-induced pancreatic cancer in syrian hamsters; majima et al. demonstrated a decrease in pancreatic hyperplasia and reduced numbers of carcinomas and ductal lesions after treatment with β-carotene, palm carotene (from palm oil, containing 60% β-carotene), and the combination of palm carotene with lower doses of green tea polyphenols. 66 another study by appel et al. evaluated the effect of β-carotene on the development of acinar pancreatic lesions induced by azaserine in rats. 79 rats administered a diet high in β-carotene or selenium developed fewer pancreatic tumors than control rats. the same study also reported fewer atypical acinar cell nodules and adenocarcinomas in rats that received vitamin C; no effect was observed with vitamin e. 79 the effect of β-carotene on pancreatic cancer in humans was evaluated in the alpha-tocopherol BetaCarotene Cancer Prevention study. 80 this study randomly allocated 29,133 Finnish male smokers aged 50-69 years to one of the following intervention groups: dl-alpha-tocopherol (a form of vitamin e), β-carotene, a combination of dl-alpha-tocopherol and β-carotene, or placebo. Patients received daily supplements for 5-8 years. the incidence of pancreatic carcinoma was 25% lower among men who received β-carotene supplements compared with those who did not, although the difference was not statistically significant. 80, 81 Vitamin D Cellular and animal studies have shown that analogues of 1α,25-dihydroxyvitamin D3, the biologically active form of vitamin D, have inhibitory activity against pancreatic cancer cell growth in vitro and in vivo. 82 Kawa et al. showed that vitamin D analogues inhibit pancreatic cancer cell growth by inducing cell cycle arrest in the G0/ G1 phase, inhibiting the production of cyclins D1, a and e, and upregulating the expression of cyclin-dependent kinase inhibitors p21 and p27. 83 in preclinical in vivo studies, vitamin D analogues were shown to inhibit the growth of pancreatic cancer cells in xenograft models in athymic nude mice. 83, 84 epidemiological studies investigating the effect of vitamin D on pancreatic cancer in humans have reported inconsistent results. in an analysis of two prospective studies conducted by skinner et al. in the cohorts of the Health Professionals Follow-up study and the nurses' Health study, a high dietary intake of vitamin D was associ ated with a reduced reViews incidence of pancreatic cancer. 85 individuals consuming ≥600 international units (iu) of vitamin D daily had a 41% lower risk of developing pancreatic cancer compared with those who consumed <150 iu daily. 85 However, in a prospective, nested case-control study conducted by stolzenberg-solomon et al. in the alphatocopherol Beta-Carotene Cancer Prevention cohort of male Finnish smokers, a high prediagnostic serum concentration of 25-hydroxy vitamin D (25(oH)D; the circulating form of vitamin D) was associated with an increased risk of pancreatic cancer (highest versus lowest quintile, >65.5 versus <32.0 nmol/l; odds ratio [or] 2.92, 95% Ci 1.56-5.48, P = 0.001). 86 in a more recent nested case-control study conducted by stolzenberg-solomon et al. in the Prostate, lung, Colorectal and ovarian screening trail cohort, prediagnostic serum 25(oH)D levels were not associated with the overall risk of pancreatic cancer. However, a positive association with risk of pancreatic cancer was observed among individuals with low estimated annual solar uvB exposure, but not among those with moderate to high uvB annual exposure. 87 a phase ii clinical trial with the vitamin D analogue seocalcitol (eB1089) in patients with advanced pancreatic cancer showed no objective antitumor activity. 88 Vitamin e vitamin e has been shown to inhibit the growth of pancre atic cancer cell lines in some 89 but not all 90 studies. alpha-tocopherol was shown to inhibit carcinogenesis in a number of animal models, as reviewed by Kelloff et al. 91 However, the alpha-tocopherol Beta-Carotene Cancer Prevention study showed a trend towards an increase in the incidence of pancreatic carcinoma and a high rate of mortality in patients receiving vitamin e supplements, although this trend was not statistically significant. 80, 81 stolzenberg-solomon et al. performed a cohort analysis of the effect of vitamin e intake (including four tocopherols and four tocotrienols) and serum levels of alpha-tocopherol on exocrine pancreatic cancer in the alpha-tocopherol Beta-Carotene Cancer Prevention study. the authors found that high serum alpha-tocopherol concentrations were associated with a low risk of pancreatic cancer (highest compared with lowest quintile, hazard ratio 0.52, 95% Ci 0.34-0.80, P = 0.03). 92 the inverse association between serum alpha-tocopherol concentration and pancreatic cancer was more pronounced in individuals who had a high intake of polyunsaturated fat.
Farnesyl transferase inhibitors
Disruption of the RAS signaling pathway by farnesyl transferase inhibitors has been proposed as a chemoprevention strategy. 93 Farnesyl transferase inhibitors (such as peri llyl alcohol, d-limonene, farnesol and geraniol) have been evaluated as chemopreventive agents for pancreatic cancer in cellular and animal models of disease.
94-97 the inhibitory activity of perillyl alcohol, geraniol and farnesol in pancreatic cancer cells is associated with induction of cell cycle arrest at the G0/G1 phase and an increase in the levels of cyclin-dependent kinase inhibitors p21 and p27. 97 Perillyl alcohol has also been reported to induce Bak-dependent apoptosis in pancreatic cancer cells while nonmalignant cells were not affected. 95 a pilot phase ii clinical trial of perillyl alcohol demonstrated some biological effects of this agent in patients with pancreatic cancer. Patients who received full perillyl alcohol treatment (288 ± 32 days) had a longer survival compared with those who did not receive full treatment (204 ± 96 days), although the difference was not statistically significant. 98 isothiocyanates isothiocyanates are compounds that are found naturally as thioglucoside conjugates (glucosinolates) in cruciferous vegetables (such as broccoli, cabbage, cauliflower, kale and Brussels sprouts). 99 the isothiocyanate sulforaphane has been studied extensively as a cancer chemo preventive agent for several types of cancer. Kallifatidis et al. showed that treatment with sulforaphane alone or in combination with trail (tumor-necrosis-factor-related apoptosisinducing ligand) reduces the growth of pancreatic tumors that are rich in tumor initiating cells or cancer stem cells by suppressing nFκB activity, cell proliferation and tumor angio genesis, and by inducing apoptosis. 100 the treatment did not have marked cytotoxic adverse effects on normal pancre atic cells. treatment with two other chemopreventive agents-resveratrol and wogonin-also sensitized pancre atic tumor initiating cells to trail-induced apoptosis, although to a lesser extent than sulforaphane. 100 other isothiocyanates, such as benzyl isothiocyanate and phenethyl isothiocyanate, are also reported to have growth inhibitory activity against pancreatic cancer in cellular and animal models of disease. For example, benzyl isothiocyanate has been shown to inhibit the growth of human pancreatic cancer cells in vitro and in xenograft models of pancreatic cancer by inducing apoptosis and causing cell cycle arrest at the G2/m phase. [101] [102] [103] treatment with phenethyl isothiocyanate inhibits BoP-induced pancreatic tumors in syrian hamsters. 104, 105 other potential chemopreventive agents several other natural or synthetic compounds have been evaluated as pancreatic cancer chemopreventive agents and showed some efficacy in preclinical cellular and/or animal studies. For example, genistein-an isoflavonoid found in soy products-has been shown to induce apoptosis and inhibit nFκB activation in BxPC3 pancreatic cancer cells via inhibition of notch-1 and nFκB signaling pathways, and to sensitize pancreatic cancer cells to docetaxel and cisplatin. 106, 107 Furthemore, el-rayes et al. showed that genistein potentiates the effect of erlotinib in BxPC3, asPC1 and CaPan2 pancreatic cancer cells through inhibition of aKt and nFκB. 108 resveratrol, a polyphenol found in grape skins, was shown to inhibit the growth of pancreatic cancer cells and enhance the antitumor activity of gemcitabine in an ortotopic mouse reViews model. 109, 110 Capsaicin, the major pungent ingredient of red chili peppers, was shown to inhibit cell viability and induce apoptosis in BxPC3 and asPC1 pancreatic cancer cells via generation of reactive oxygen species and disruption of mitochondrial membrane potential, and to suppress the growth of asPC1 cells in a xenograft model of pancreatic cancer. 111 3,3'-Diindolylmethane (Dim) is an acid condensation product of indole-3-carbinol (i3C), which is found in cruciferous vegetables. Dim, as well as its more bioavailable analogue B-Dim, inhibits cell growth and induces Par4 apoptosis in l3.6pl and Colo 357 pancre atic cancer cells. 112 Pretreatment with B-Dim sensitized l3.6pl, Colo 357 and BxPC3 pancreatic cancer cells to gemcitabine and cisplatin through activation of Par4-induced apoptosis and inactivation of the aKt signaling pathway. 112 in another study, B-Dim was shown to potentiate the effect of erlotinib in BxPC3 cells in vitro and in an orthotopic model of pancreatic cancer with BxPC3 cells. 113 the combination of B-Dim and erlotinib was much more effective as an antitumor agent compared with either agent alone. 113 metformin, which is a drug that is widely prescribed for the treatment of type 2 diabetes, has been shown to prevent the development of BoP-induced pancreatic cancer in syrian hamsters, 114 and to inhibit the growth of pancreatic cancer cells (miaPaca2 and PanC1) in xenograft models in athymic nude mice. 115 an epidemiological study showed a protective effect of metformin against pancreatic cancer in patients with type 2 diabetes. 116 treatment with metformin was associated with a 62% lower risk of developing pancreatic cancer compared with metformin nonuse (or 0.38, 95% Ci 0.22-0.69, P = 0.001). 116 this study suggests that metformin could be used as a preventive strategy against pancreatic cancer in a subset of patients with type 2 diabetes. this finding warrants further confirmation in larger studies.
Clinical recommendations for prevention
to date, the best preventive strategy against pancreatic cancer is risk reduction, including smoking cessation, weight reduction, a diet high in fruits and vegetables, and regular exercise. 117, 118 although several natural and synthetic agents are under development as potential chemopreventive agents for pancreatic cancer, currently there are no clinical recommendations for prevention of pancre atic cancer using pharmacological agents. although beneficial effects are not consistently reported in all studies, the most promising evidence for chemoprevention exists for vitamin D, curcumin and, to a lesser extent, for aspirin (short-term use only). effort is being made at the preclinical level to identify new chemo preventive agents and define their mechanisms of action. no definitive clinical recommendations can be made until further randomized clinical trials and observational studies are conducted.
several obstacles must be overcome to develop chemopreventive agents for pancreatic cancer. one such challenge is developing potential surrogate markers that
can be used to demonstrate that a particular chemopreventive agent is effective. although precursor lesions such as advanced Panins have been identified, these lesions cannot be reliably detected without histological analysis of resected pancreatic specimens. thus, it is essential to find novel approaches to identify these lesions, such as molecular imaging or a biomarker that is correlated with these lesions. Defining potential surrogate end point markers could also reduce the number of patients needed and the time required to perform high quality pancreatic cancer chemoprevention trials.
emphasis also needs to be placed on defining which individuals have a high risk of developing pancreatic cancer-in whom the benefits associated with a chemoprevention strategy will outweigh any possible risks. our center, along with others, is exploring sophisticated modeling techniques that incorporate clinical, demographic and genetic information to create risk stratification models for pancreatic cancer development. Presently, the only group of patients who would be candidates for a chemoprevention trial would be unaffected members from pancreatic-cancer-prone families, although chemoprevention strategies might prove useful as early interventions in patients who present with premalignant lesions or at the early stages of carcinogenesis.
Combinational chemoprevention seems to be a promising strategy for enhanced chemopreventive action through the synergistic effects of multitargeting agents combined on the basis of detailed understanding of their mechanisms of action. enhanced delivery methods (for example, use of liposomal curcumin) could also increase the circulation levels of chemopreventive agents that have low bioavailability. several chemopreventive agents are currently being tested in clinical trials for lung, prostate, breast and colon cancer; once completed the results might provide useful information for designing pancreatic cancer chemoprevention trials.
Conclusions
Pancreatic cancer has a poor prognosis, and the survival rate of patients with pancreatic cancer has not substantially improved over the past few decades. several natural and synthetic compounds have been evaluated as pancreatic cancer chemopreventive agents and have been shown to have various degrees of efficacy in cellular and in vivo animal models. mechanistic studies suggest that many natural cancer chemopreventive agents could act as multitargeting agents affecting several pathways in pancreatic carcinogenesis. Chemopreventive agents have also been reported to potentiate the effect of standard chemotherapeutic drugs (such as gemcitabine or erlotinib), demonstrating the potential use of chemo preventive agents in the realm of standard chemo therapy. Few clinical trials with potential pancre atic cancer chemopreventive agents have been completed and some are in early phases. Definitive, large-scale, randomized, clinical trials are necessary to determine the clinical efficacy of promising pancreatic cancer chemopreventive agents. reViews the success of any chemopreventive strategy will depend on defining the underlying mechanisms of action of the cancer chemopreventive agents through rigorous preclinical research combined with improvements in our ability to identify premalignant lesions and develop surrogate end-point markers for clinical trials. Chemoprevention may prove to be tremendously valuable for individuals who are at a high risk of developing pancreatic cancer-including individuals with known risk factors for pancreatic cancer and patients who present with premalignant lesions.
Review criteria
PubMed was searched in October 2009 for englishlanguage publications using the terms: "pancreatic cancer", "chemoprevention", "prevention", "antioxidant therapy". Articles were selected on the basis of their relevance, and additional articles were identified from their reference lists. Reviews have been cited when appropriate to limit the number of references. The website http://www.clinicaltrials.gov was used to identify ongoing pancreatic-cancer-related clinical trials with chemopreventive agents.
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